- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Nasus Pharma advances intranasal epinephrine powder for anaphylaxis | 1 | Investing.com | ||
| NASUS PHARMA Aktie jetzt für 0€ handeln | |||||
| Mo | Nasus Pharma, Ltd.: Nasus Pharma CEO Issues 2025 Letter to Shareholders | 100 | GlobeNewswire (Europe) | TEL AVIV, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma", "Nasus" or the "Company"), a clinical-stage pharmaceutical company focused on the development of... ► Artikel lesen | |
| Mo | Nasus Pharma Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 18.12. | Citizens initiates Nasus Pharma stock with Market Outperform rating | 1 | Investing.com | ||
| 20.11. | Nasus Pharma appoints Eyal Rubin as new CFO to strengthen leadership | 2 | Investing.com | ||
| 20.11. | Nasus Pharma stärkt Führungsteam mit neuem CFO Eyal Rubin | 1 | Investing.com Deutsch | ||
| 20.11. | Nasus Pharma, Ltd.: Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer | 114 | GlobeNewswire (Europe) | TEL AVIV, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma", "Nasus" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative... ► Artikel lesen | |
| 18.11. | Nasus Pharma begins phase 2 trial of needle-free epinephrine for anaphylaxis | 1 | Investing.com | ||
| 18.11. | Nasus Pharma, Ltd.: Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed | 179 | GlobeNewswire (Europe) | The Phase 2 study is designed to address regulatory approval considerations by comparing bioavailability and pharmacokinetics of NS002 against EpiPen Previous clinical study demonstrated NS002 can... ► Artikel lesen | |
| 18.11. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 06.11. | Health Canada approves Nasus Pharma's phase 2 trial for nasal epinephrine | 1 | Investing.com | ||
| 03.11. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 08.10. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 30.09. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 29.09. | Laidlaw initiates Nasus Pharma stock with Buy rating on anaphylaxis drug | 2 | Investing.com | ||
| 05.09. | Nasus Pharma Ltd - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 14.08. | Nasus Pharma completes $10 million initial public offering | 1 | Investing.com | ||
| 14.08. | Nasus Pharma, Ltd.: Nasus Pharma Announces Closing of Initial Public Offering | 207 | GlobeNewswire (Europe) | TEL AVIV, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative... ► Artikel lesen | |
| 13.08. | Nasus Pharma Opens At $8, IPO Priced At $8 | 3 | Investing.com | ||
| 13.08. | Nasus Pharma prices its IPO at $8 per share | 2 | Seeking Alpha |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|
Das Unternehmen NASUS PHARMA LTD kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,100 (+1,35 %) liegt der Kurs bei 7,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NASUS PHARMA LTD finden Sie auf Wallstreet Online.